Hsbc Holdings PLC Reduces Stock Position in Natera, Inc. $NTRA

Hsbc Holdings PLC lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 42.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 60,653 shares of the medical research company’s stock after selling 44,352 shares during the quarter. Hsbc Holdings PLC’s holdings in Natera were worth $12,070,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Robinhood Asset Management LLC acquired a new position in shares of Natera during the 4th quarter valued at about $12,981,000. J. Safra Sarasin Holding AG acquired a new stake in Natera during the fourth quarter worth about $2,825,000. UBS Group AG increased its position in Natera by 19.4% during the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after purchasing an additional 71,355 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Natera by 25.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 45,835 shares of the medical research company’s stock worth $11,476,000 after purchasing an additional 9,424 shares during the period. Finally, Dakota Wealth Management purchased a new position in Natera during the fourth quarter worth about $1,356,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00. Following the transaction, the insider directly owned 134,643 shares in the company, valued at $36,744,074.70. This represents a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,872 shares of company stock worth $39,627,696 in the last three months. Company insiders own 5.05% of the company’s stock.

Analyst Ratings Changes

NTRA has been the subject of several analyst reports. UBS Group set a $260.00 price target on shares of Natera in a research note on Wednesday, June 24th. Wells Fargo & Company lifted their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Wolfe Research began coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Stock Performance

Natera stock opened at $264.22 on Thursday. The company’s 50 day simple moving average is $237.88 and its 200-day simple moving average is $221.08. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04. The company has a market capitalization of $37.84 billion, a price-to-earnings ratio of -162.10 and a beta of 1.51.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.